JUMP REPORT
Avg Daily Volume: 795,234 Market Cap: 812.56M
Sector: Services Short Interest: 14.11
EARNINGS EXPECTATIONS:
THIS QTR: EPS: .03/share REV: 37.99/M
___________________________________________________________
LAST QTR: EPS: .01/share ACTUAL: .04/share (BEAT)
____________________________________________________________
NEXT QTR: EPS: .01/share REV: 38.9/M
______________________________________________________
FULL YR: EPS: .13/share REV: 164.68/M
______________________________________________________
*These are the base metrics we will be watching against the actual release numbers
__________________________________________________________________
BEAT/MISS RECORD: –% OF THE TIME THEY BEAT ESTIMATES
PRIOR ‘JUMP ZONE’ MOVES (LAST 3 QTRS %) -13.59, 9.11, 12.55
EXPECTED JUMP MOVE: 10-15%
——–
*** With market volatility at extremes during the coronavirus pandemic there is greater risk in trading these events which may not react as they would under normal market conditions. Please take extra caution before trading.
Links To Latest News and Headlines
We know that hedge funds generate strong, risk-adjusted returns over the long run, therefore imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, smart money investors have to conduct complex analyses, spend many resources and use tools that are not always […]
TORONTO and CHICAGO, July 19, 2021 (GLOBE NEWSWIRE) — Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSX: MDP) (OTCQX: MEDXF) is pleased to announce the appointment of Marcel Konrad as Chief Financial Officer of the Company, effective immediately. Mr. Konrad succeeds Roland Boivin, who is stepping down after nearly a decade in the role. Mr. Boivin has agreed to stay on in an advisory capacity in order to help ensure an orderly transition of responsibilities to Mr. Konrad over the ne
SOUTH SAN FRANCISCO, Calif., July 15, 2021 (GLOBE NEWSWIRE) — CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced it will report financial results for the second quarter 2021 after market close on Thursday, July 29, 2021. Company management will host a corresponding conference call beginning at 1:30 p.m.
AlloCare launches in Android Play Store, and is now available on both iOS and Android for all transplant patientsSOUTH SAN FRANCISCO, Calif., July 01, 2021 (GLOBE NEWSWIRE) — CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced that AlloCare, the app developed by CareDx for patients looking to manage their
Dr. Valantine brings deep transplant and diversity leadership expertise to the CareDx board SOUTH SAN FRANCISCO, Calif., June 30, 2021 (GLOBE NEWSWIRE) — CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announces that Hannah Valantine, MD has joined CareDx’s Board of Directors. Dr. Valantine is a Professor of Me
StockJumpers analysis and trade plans are uploaded generally 1 HOUR BEFORE MARKETS CLOSE (3PM EST) for most events.
“I’m sorry, this content is for members only. To access this content, you must log in with your membership credentials – OR if you are not a member yet, visit our registration page here and get signed up Looking forward to having you on-board ASAP”
There is a significant amount of data behind the scenes involved in the analysis and trade plan tab above, that does not get put into the report. Too much information for traders often confuses things – so this is stripped down to only what is needed to make the best possible decision(s) on trading the trajectory.
NOTICE: All data on this site has been published for informational and educational purposes only and does not constitute an offer to sell nor a solicitation of an offer to buy any security which may be referenced here or in our websites. StockJumpers is not an Investment Adviser and relies on the publisher’s exemption as defined in Section 401(f) of the Uniform Securities Act, and provides no personal advice or recommendations. The services and published information contained herein is for non-commercial, educational use and display. StockJumpers and any of its affiliates does not represent that the securities or services discussed are suitable for any investor. You should assume that StockJumpers and or its management has or will take a position in the stock, whether it is stated or not. You are further advised not to rely on any information contained in this report and associated websites in the process of making a fully informed investment decision. Trading is risky and you can lose your investment. For the complete risk disclosure and other legal information please review the full Terms of Use Agreement.